Top Markets
Coin of the day
Hindustan Bio Sciences Limited Hindustan Bio Sciences Limited

Hindustan Bio Sciences Limited

HINDBIO
Rank in Stocks #38830
Hindustan Bio Sciences Ltd. specializes in the trade of pharmaceuticals and... Hindustan Bio Sciences Ltd. specializes in the trade of pharmaceuticals and medical supplies. Its extensive product catalog encompasses liquid injectables, various liquid and dry syrups, ophthalmic, otic, and nasal drops, and pre-filled syringes. The company also provides a range of sterile and non-sterile ointments, alongside tablets and capsules. Established in 2000, its headquarters are located in Hyderabad, India.
Share Price
$0.07647863
Market Cap
$783.97K
Change (1 day)
0.87%
Change (1 year)
-22.02%
Country
IN
Trade Hindustan Bio Sciences Limited (HINDBIO)

Category

P/E ratio for Hindustan Bio Sciences Limited (HINDBIO)
P/E ratio as of 2026 TTM: 0
According to Hindustan Bio Sciences Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Hindustan Bio Sciences Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.